7 insiders reported 24 Form 4 transactions for CytomX Therapeutics, Inc. (CTMX) over the past 18 months (most recent 2026-08-05). Recent activity: Carvajal Alejandra (Chief Legal Officer) Buy 100,000 shares, Ogden Christopher (Chief Financial Officer) Sell 1,624 shares, McCarthy Sean A. (CEO) Sell 118,969 shares, BELVIN MARCIA (SVP, Chief Scientific Officer) Sell 31,492 shares, Chu Yu-Waye (Chief Medical Officer) Sell 21,279 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Carvajal Alejandra | Chief Legal Officer | Buy | 100,000 | $0 |
| 2026-06-17 | Ogden Christopher | Chief Financial Officer | Sell | 1,624 | $4,953 |
| 2026-03-19 | McCarthy Sean A. | CEO | Sell | 118,969 | $763,781 |
| 2026-03-19 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 31,492 | $202,179 |
| 2026-03-19 | Chu Yu-Waye | Chief Medical Officer | Sell | 21,279 | $136,611 |
| 2026-03-19 | Ogden Christopher | Chief Financial Officer | Sell | 19,323 | $124,054 |
| 2026-02-04 | BELVIN MARCIA | SVP, Chief Scientific Officer | Buy | 60,000 | $0 |
| 2026-02-04 | Chu Yu-Waye | Chief Medical Officer | Buy | 75,000 | $0 |
| 2026-02-04 | McCarthy Sean A. | CEO | Buy | 210,000 | $0 |
| 2026-02-04 | Ogden Christopher | Chief Financial Officer | Buy | 90,000 | $0 |
| 2026-02-04 | Lester Rachael | Chief Business Officer | Buy | 20,000 | $0 |
| 2025-11-10 | McCarthy Sean A. | CEO | Sell | 101,793 | $462,140 |
| 2025-06-17 | BELVIN MARCIA | SVP, Chief Scientific Officer | Buy | 37,500 | $0 |
| 2025-06-17 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 13,884 | $37,348 |
| 2025-06-17 | Ogden Christopher | Chief Financial Officer | Sell | 1,641 | $4,841 |
| 2025-06-17 | Ogden Christopher | Chief Financial Officer | Buy | 37,500 | $0 |
| 2025-06-17 | Ogden Christopher | Chief Financial Officer | Sell | 10,614 | $28,552 |
| 2025-06-17 | McCarthy Sean A. | CEO | Buy | 150,000 | $0 |
| 2025-06-17 | McCarthy Sean A. | CEO | Sell | 55,511 | $149,325 |
| 2025-03-20 | ROWLAND LLOYD A | General Counsel | Sell | 10,203 | $6,122 |
| 2025-03-20 | Chu Yu-Waye | Chief Medical Officer | Sell | 4,025 | $2,415 |
| 2025-03-20 | McCarthy Sean A. | CEO | Sell | 37,656 | $22,594 |
| 2025-03-20 | BELVIN MARCIA | SVP, Chief Scientific Officer | Sell | 19,512 | $11,707 |
| 2025-03-20 | Ogden Christopher | Chief Financial Officer | Sell | 8,551 | $5,131 |
Source: SEC Form 4 filings · as of 2026-08-05